天演药业（苏州）有限公司 ADAGENE Mediaroom - PR Newswire APAC

Search

天演药业（苏州）有限公司 ADAGENE

Latest News

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) ...

2024-01-17 20:00 2871

Adagene to Present at Investor and Scientific Conferences in September

- Adagene's CEO and President of R&D, Dr. Peter Luo, participating in SITC webinar onSeptember 22 f...

2023-09-08 10:45 2033

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-cla...

2022-05-27 09:30 5276

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

SAN DIEGO and SUZHOU, China, March 16, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG)...

2022-03-16 19:00 2679

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

* New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeli...

2022-03-09 10:21 2893

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

SAN DIEGO and SUZHOU, China, Mar. 2, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), ...

2022-03-02 19:00 3110